Back to Search Start Over

Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper.

Authors :
Perucca, Emilio
French, Jacqueline A.
Aljandeel, Ghaieb
Balestrini, Simona
Braga, Patricia
Burneo, Jorge G.
Felli, Augustina Charway
Cross, J. Helen
Galanopoulou, Aristea S.
Jain, Satish
Jiang, Yuwu
Kälviäinen, Reetta
Lim, Shih Hui
Meador, Kimford J.
Mogal, Zarine
Nabbout, Rima
Sofia, Francesca
Somerville, Ernest
Sperling, Michael R.
Triki, Chahnez
Source :
Epilepsia (Series 4). Mar2024, Vol. 65 Issue 3, p533-541. 9p.
Publication Year :
2024

Abstract

A variety of terms, such as "antiepileptic," "anticonvulsant," and "antiseizure" have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English‐language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named "antiseizure medications". This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term "antiseizure" to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having "antiepileptogenic" or "disease‐modifying" effects. A more‐refined terminology to describe precisely these actions needs to be developed. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00139580
Volume :
65
Issue :
3
Database :
Academic Search Index
Journal :
Epilepsia (Series 4)
Publication Type :
Academic Journal
Accession number :
176104996
Full Text :
https://doi.org/10.1111/epi.17877